+838.2%
RIOT vs MRNA
+786.4%
+51.8%
-95.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -8.5% | -2.2% | -6.3% | -8.1% |
| 7D | -7.4% | -12.7% | +5.3% | -5.5% |
| 30D | +15.8% | -20.7% | +36.4% | +19.9% |
| 3M | -22.6% | +46.3% | -68.9% | -27.5% |
| 6M | -31.4% | +305.2% | -336.7% | -55.3% |
| YTD | +28.1% | +561.2% | -533.1% | -26.9% |
| 1Y | +27.0% | +772.1% | -745.1% | -32.6% |
| 3Y | +43.4% | +147.0% | -103.6% | -2.3% |
| 5Y | -55.1% | -26.1% | -29.1% | -61.7% |
| All | +838.2% | +786.4% | +51.8% | +542.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling